Caitong International Asset Management’s Avita Medical RCEL Stock Holding History

Caitong International Asset Management’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$194	Buy	+47	New	+$203	﹤0.01%	2014

Other funds holding RCEL

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Caitong International Asset Management's RCEL Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Avita Medical (RCEL) in Q2 2026: 47 shares worth $194. The stake represents ﹤0.01% of the portfolio and ranks #2014 among its holdings.

73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

Caitong International Asset Management held 47 shares of Avita Medical worth $194 as of Q2 2026.
Avita Medical was a new Caitong International Asset Management position in Q2 2026.
Avita Medical made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2014 holding.
73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.